Results 261 to 270 of about 169,984 (290)

MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research

Medical Oncology, 2010
Jianfeng Wang
exaly  

Biochemical characteristics of a textile dye degrading extracellular laccase from a Bacillus sp. ADR

Bioresource Technology, 2011
Amar A Telke, Dayanand C Kalyani, Sanjay Govindwar   +2 more
exaly  

Selection and use of Alternative Dispute Resolution (ADR) in construction projects — Past and future research

International Journal of Project Management, 2016
Chia Kuang Lee, Tak Wing Yiu, Sai On Cheung   +2 more
exaly  

ADR

2012
openaire   +1 more source

Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling

Chemico-Biological Interactions, 2017
Zhenbing Chen, Yufeng Ding
exaly  

The valuation of ADR IPOs

Journal of International Financial Markets, Institutions and Money, 2018
Chengbo Fu, Steven X Zheng
exaly  

Human resource management and ADR practices in Ireland

International Journal of Human Resource Management, 2012
Paul Teague
exaly  

ADR

2007
openaire   +1 more source

Barbigerone reverses multidrug resistance in breast MCF‐7/ADR cells

Phytotherapy Research, 2018
Lijuan Chen, Lijuan Chen
exaly  

LE ADR PROFILI GENERALI

2010
Il saggio si occupa delle ADR alla luce della direttiva comunitaria n. 52 del 2008 e del d. lgs. 28/2010 che ha recepito nel diritto interno la direttiva stessa. Il contributo muove dalle prime raccomandazioni del 1998 e del 2001 della Commissione europea e dal libro verde sulle ADR del 2006.
openaire   +4 more sources